ACAD vs WAY: Which Stock Is the Better Buy?
ACADIA Pharmaceuticals Inc. and Waystar Holding Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ACAD vs WAY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| ACADIA Pharmaceuticals Inc. (ACAD) | Waystar Holding Corp. (WAY) | |
|---|---|---|
| Market cap | $3.7B | $3.6B |
| Revenue (latest FY) | $1.07B | $1.10B |
| Net income (latest FY) | $391.00M | $112.09M |
| Revenue growth (5y CAGR) | 19.4% | 16.0% |
| Net margin | 36.5% | 10.2% |
| Return on equity | 31.9% | 2.9% |
| P/E ratio | 9.7 | 28.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ACAD vs WAY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ACAD's full financials → Open WAY's full financials →More comparisons
Frequently asked questions
Which is bigger, ACAD or WAY?
ACADIA Pharmaceuticals Inc. is larger by market capitalization — $3.7B versus $3.6B.
Which grows faster, ACAD or WAY?
Over the last five fiscal years, ACADIA Pharmaceuticals Inc. grew revenue faster — 19.4%/yr versus 16.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.